Rhythm Pharmaceuticals financials
$95.71−2.89%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.3M | $60.1M | $57.3M | $51.3M | $48.5M | $32.7M | $41.8M | $33.3M | $29.1M | $26.0M | $24.2M | $22.5M |
| Gross profit | $62.3M | $53.0M | $52.5M | $45.8M | $43.0M | $29.1M | $38.0M | $29.4M | $26.1M | $23.2M | $21.0M | $20.1M |
| Gross margin | 87.5% | 88.1% | 91.6% | 89.3% | 88.6% | 88.8% | 90.9% | 88.5% | 89.9% | 89.2% | 86.7% | 89.3% |
| Operating income | -$48.6M | -$52.4M | -$47.1M | -$52.7M | -$45.3M | -$47.0M | -$41.3M | -$43.9M | -$40.5M | -$139.9M | -$41.3M | -$44.0M |
| Net income | -$50.4M | -$56.7M | -$48.8M | -$54.3M | -$48.0M | -$50.8M | -$44.6M | -$45.0M | -$33.6M | -$141.4M | -$41.6M | -$44.2M |
| Net margin | −70.7% | −94.4% | −85.3% | −105.8% | −98.9% | −155.4% | −106.7% | −135.2% | −115.4% | −544.4% | −171.8% | −196.2% |
| Diluted EPS | $-0.73 | $-0.83 | $-0.73 | $-0.82 | $-0.75 | $-0.81 | $-0.72 | $-0.73 | $-0.55 | $-2.35 | $-0.70 | $-0.76 |
| EBITDA | -$48.3M | -$52.1M | -$46.8M | -$52.3M | -$44.9M | -$46.6M | -$40.9M | -$43.5M | -$39.7M | -$139.9M | -$41.3M | -$39.2M |
| Operating cash flow | -$9.2M | -$44.2M | -$25.4M | -$26.6M | -$23.3M | -$40.4M | -$18.8M | -$25.2M | -$29.1M | -$40.7M | -$29.4M | -$29.3M |
| Free cash flow | -$9.2M | -$44.2M | -$26.3M | -$26.6M | -$23.3M | -$40.4M | -$18.8M | -$25.2M | -$29.1M | -$40.7M | -$29.4M | -$29.3M |
| Diluted shares | 68.6M | 68.0M | 66.9M | 66.3M | 63.7M | 63.1M | 61.6M | 61.2M | 61.0M | 60.1M | 59.2M | 57.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $65.6M | $62.1M | $54.3M | $52.1M | $135.6M | $106.1M |
| Short-term investments | $265.3M | $278.5M | $334.6M | $364.0M | $155.4M | $208.4M |
| Total debt | $106.1M | $108.5M | $108.2M | $109.0M | $109.8M | $109.5M |
| Total assets | $437.3M | $442.3M | $480.2M | $506.9M | $372.7M | $386.7M |
| Total liabilities | $220.0M | $204.7M | $210.2M | $211.2M | $239.2M | $223.6M |
| Shareholders' equity | $103.0M | $122.9M | $139.1M | $148.8M | -$11.9M | $18.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology